AI in Dentistry Market (2026-2036)

The growth of this market is mainly driven by the alignment between detection and treatment inside the same business, since a dental practice both identifies a finding and delivers the procedure that follows and therefore retains the revenue that software generates, by a dedicated class II regulation reviewed by the Dental panel that gives camera-based analysis a defined clearance route in both home-use and in-office settings, by consolidation of practices into dental support organisations able to standardise one configuration across hundreds of sites, and by dental benefit payers purchasing the same analytical capability to review submitted radiographs against claimed procedures. Dentistry is also almost entirely fee-for-service and privately funded, so a purchasing decision rests on practice economics rather than on a coverage determination, and that removes the approval cycle that governs adoption in every other clinical application of artificial intelligence.

However, factors such as the absence of any public payment pathway that a vendor can target, the small average size and limited capital budget of an independent dental practice, the opposing commercial interests of practices and dental benefit payers purchasing the same capability, and the overtreatment concern that follows from detection and treatment sitting in one business are expected to restrain the growth of this market to some extent. Medicare excludes dental services from payment altogether, so no coverage decision, procedure code or quality measure exists for a vendor to win, and adoption therefore proceeds practice by practice or through group purchasing rather than through a national programme.

42 U.S.C. 1395y(a)(12), which excludes from Medicare payment expenses for services in connection with the care, treatment, filling, removal or replacement of teeth or structures directly supporting teeth, except that payment may be made under part A for inpatient hospital services where the individual requires hospitalisation in connection with the provision of such dental services because of the underlying medical condition and clinical status or because of the severity of the dental procedure. There is consequently no public coverage pathway in dentistry at all, no procedure code to obtain, no coverage determination to win and no quality measure to attach a product to, and the entire payment architecture that governs adoption of software in cardiology, radiology, dermatology and oncology simply does not exist here. Dentistry is funded by dental benefit plans with annual maximums and by patient out-of-pocket spending, and the practice itself is the purchaser. A vendor therefore sells to a small business on a commercial case rather than to a health system on a clinical one, which makes the sales motion closer to practice software than to medical device software.

Detection and treatment sit inside the same business, which inverts the economics that constrain artificial intelligence everywhere else in medicine. In cardiology or dermatology a detection output generates downstream testing that somebody other than the purchaser has to fund, so the clinical case is strong and the commercial case is weak. In dentistry the practice that identifies a carious lesion on a bitewing radiograph is the practice that restores it and bills for the restoration, so software that surfaces findings a clinician would otherwise have missed produces revenue for the buyer within the same appointment. That is the clearest return on investment available to any clinical artificial intelligence product, and it is the reason adoption in dentistry has run ahead of adoption in specialties with far larger research budgets.

If a practice profits from each additional finding, the party paying for the treatment has a reason to question whether every finding warranted it, and dental benefit payers have responded by acquiring the same analytical capability and applying it to submitted radiographs in order to test claimed procedures against the images supporting them. One technology therefore has two customers whose interests oppose each other, the practice seeking to identify and document more treatable disease and the payer seeking to confirm that the documented disease justified the claim, and both are paying for it. No other clinical artificial intelligence market has this structure, and the payer side is the faster-growing of the two because a single plan deployment covers claims from thousands of practices.

21 CFR 872.1770, the class II regulation reviewed by the Dental panel and cleared through the 510(k) pathway, under which a dental image analyzer, product code SBC, is a prescription home-use device whose software collects and analyses patient-specific optical camera-based intraoral images that dental professionals use as a diagnostic aid for oral health conditions and to monitor treatment progress, and a dental image analyzer for in-office use, product code SHQ, is a prescription device whose software collects and analyses patient-specific intraoral camera images as an aid to diagnosing oral health conditions covers camera-based analysis, and the separation of the two product codes by setting is commercially significant. The home-use code supports remote monitoring between appointments, where a patient captures intraoral images and software reports on treatment progress, which is how orthodontic aligner monitoring at scale became possible without an in-person visit for each check. The in-office code covers chairside analysis during the appointment itself. Both are prescription devices reviewed by the Dental panel, so a vendor entering either route deals with reviewers whose reference points are dental rather than radiological, and whose expectations on clinical evidence differ accordingly from those applied to radiological software elsewhere in medicine.

Radiograph-based analysis reaches the market under a different set of rules, since 21 CFR 892.2090, the class II classification for radiological computer assisted detection and diagnosis software, which carries product code QBS for fracture and QDQ for lesions suspicious for cancer, and 21 CFR 892.2070, the class II classification for a medical image analyzer, product code MYN govern software that analyses radiographic images, and the dental regulation is written around intraoral camera and optical images rather than X-rays. A practice buying caries detection on bitewing radiographs and remote monitoring on camera images is therefore buying two products cleared under two regulations reviewed by two different panels, and a vendor seeking to serve both carries two regulatory programmes, which is a substantial part of the reason few suppliers hold a strong position in both radiographic detection and camera-based monitoring.

The European Union Artificial Intelligence Act, which entered into force on 1 August 2024 and became generally applicable on 2 August 2026, and under which high-risk artificial intelligence systems embedded in products regulated by the sectoral legislation listed in Annex I, which includes medical devices, apply from 2 August 2028 following the extension of that transition period by the AI Omnibus applies in Europe alongside the Medical Device Regulation, under which software intended to inform diagnostic decisions carries a higher classification than the imaging hardware it runs on. European dentistry is funded through a mixture of statutory and private cover that varies widely by country, with substantial private payment in Germany and Switzerland and largely private provision in several other markets, so the practice economics that drive adoption in North America apply unevenly across the region. The absence of a single payer in any large European dental market also means the claims review opportunity that is growing fastest in the United States has no direct equivalent at comparable scale. National dental services in the countries that operate them also set fees centrally, so a practice cannot convert an additional finding into additional revenue at will, which removes the production argument that drives adoption in North America, so European vendors have built toward chairside efficiency and laboratory automation instead, and the regional supply reflects that difference rather than any lag in technology.